Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Victoria Rothwell

Gastroenterology Charlotte, NC Medical Doctor

NPI 1316365067 CMS profile 4223333

300 Billingsley Rd Ste 200, Charlotte, NC 28211

Open in the dashboard

General payments

$22,479

1,282 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Victoria Rothwell of Charlotte, NC is reported in the CMS Open Payments database as having received $22,479 across 1,282 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,381 329
2024 General $3,912 216
2023 General $3,110 197
2022 General $3,892 232
2021 General $3,974 236
2020 General $1,211 72

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Victoria Rothwell
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Victoria Rothwell were reported at $6,381. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Victoria Rothwell Gastroenterology median Middle half National median
2019 $0 $417 $126–$1,100 $163
2020 $1,211 $224 $74–$624 $114
2021 $3,974 $352 $106–$1,054 $132
2022 $3,892 $448 $129–$1,270 $149
2023 $3,110 $533 $150–$1,390 $160
2024 $3,912 $605 $160–$1,606 $164
2025 $6,381 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. AbbVie, Inc. $5,064 305 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $3,123 218 payments
  3. Janssen Biotech, Inc. $1,885 83 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $1,625 91 payments
  5. QOL Medical, LLC $1,193 68 payments
  6. Celgene Corporation $964 69 payments
  7. VIVUS, Inc. $847 49 payments
  8. Pfizer Inc. $810 44 payments
  9. Genzyme Corporation $710 38 payments
  10. Ironwood Pharmaceuticals, Inc $688 40 payments
  11. Other $5,571 277 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $22,206 1,278 payments
  2. Education $274 4 payments
Products named General payments · program years 2020–2025
  1. XIFAXAN $1,920 121 payments
  2. RINVOQ $1,593 100 payments
  3. ENTYVIO $1,301 75 payments
  4. STELARA $1,266 61 payments
  5. SKYRIZI $1,136 60 payments
  6. CREON $1,079 68 payments
  7. ZEPOSIA $964 69 payments
  8. TREMFYA $949 35 payments
  9. LINZESS $902 74 payments
  10. ZENPEP $898 41 payments
  11. Other $13,960 786 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

835

Median for Gastroenterology: 569

Drug cost

$369,464

Median for Gastroenterology: $104,976

Branded share of claims

35%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Entyvio Vedolizumab Brand 13 $110,889
Xeljanz Tofacitinib Citrate Brand 12 $65,798
Zenpep Lipase/Protease/Amylase Brand 22 $61,415
Linzess Linaclotide Brand 57 $52,184
Motegrity Prucalopride Succinate Brand 25 $21,505
Trulance Plecanatide Brand 22 $20,728
Mesalamine Er Mesalamine Brand 11 $6,739
Clenpiq Sod Picosulf/Mag Ox/Citric Ac Brand 31 $5,333
Dexlansoprazole Dr Dexlansoprazole Brand 11 $4,406
Lubiprostone Generic 20 $4,269

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$67,203

Medicare's payments for the services billed

Medicare patients

231

Average age 73

Services billed

1,019

158 women, 73 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Diabetes 34%
Depression 28%
Ischemic heart disease 27%
Chronic kidney disease 25%
COPD 18%
Heart failure 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 35 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
$360 — —
XIFAXAN
$340 — —
ENTYVIO
$326 13 —
RINVOQ
$268 — —
Sucraid
$178 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 35 with Patron

Records

1,282 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record